Biotest AG (XTER:BIO3) Receivables Turnover : 1.14 (As of Sep. 2024)

View and export this data going back to 1987. Start your Free Trial

What is Biotest AG Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Biotest AG's Revenue for the three months ended in Sep. 2024 was €150.7 Mil. Biotest AG's average Accounts Receivable for the three months ended in Sep. 2024 was €131.7 Mil. Hence, Biotest AG's Receivables Turnover for the three months ended in Sep. 2024 was 1.14.

Biotest AG Receivables Turnover Historical Data

The historical data trend for Biotest AG's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotest AG Receivables Turnover Chart

Biotest AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Receivables Turnover

Get a 7-Day Free Trial

3.70

4.33

4.62

4.45

5.08

Biotest AG Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Receivables Turnover	Get a 7-Day Free Trial															1.25	1.04	1.24	0.94	1.14

Competitive Comparison of Biotest AG's Receivables Turnover

For the Biotechnology subindustry, Biotest AG's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biotest AG's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biotest AG's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Biotest AG's Receivables Turnover falls into.

Biotest AG Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Biotest AG's Receivables Turnover for the fiscal year that ended in Dec. 2023 is calculated as

	Receivables Turnover (A: Dec. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2023 )	/ (	(Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )
=	684.6	/ (	(124.5	+	145.2)	/	2 )
=	684.6	/	134.85
=	5.08

Biotest AG's Receivables Turnover for the quarter that ended in Sep. 2024 is calculated as

	Receivables Turnover (Q: Sep. 2024 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Sep. 2024 )	/ (	(Accounts Receivable (Q: Jun. 2024 )	+	Accounts Receivable (Q: Sep. 2024 ))	/	count )
=	150.7	/ (	(131.3	+	132.1)	/	2 )
=	150.7	/	131.7
=	1.14

Biotest AG (XTER:BIO3) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Biotest AG Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Biotest AG's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Biotest AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biotest AG (XTER:BIO3) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

0N70:UK BIO3:Austria

Address

Landsteinerstrasse 5, Dreieich, DEU, 63303

Website

https://www.biotest.com

Biotest AG is a supplier of biological medicines. The company produces its products from human blood plasma or manufactured by using biotechnology methods. It is engaged in the area of hematology, clinical immunology, and intensive care medicine. The operating business segments are Therapy, Plasma and Services, and Other segments. It generates maximum revenue from the Therapy segment. Geographically, it derives a majority of revenue from Central Europe and also has a presence in other countries.

Executives

Dr. Katrin Bernöster	Vice President Corp. Project + Portfolio Management
Dr. Martin Reinecke	Senior Vice President plasma alliances and proteine supply
Stephan Fleck	Vice President Corporate Controlling
Dr. Jörg Schüttrumpf	VP Corp. Research &Development
Michael Moritz	VP CC Materials & Facility Management

Biotest AG Headlines

No Headlines